Company Overview of CSL Behring UK Limited
CSL Behring UK Limited engages in the research, development, manufacture, and marketing of plasma-derived and recombinant therapies worldwide. Its therapies are used for the treatment of various serious and rare conditions, such as coagulation (bleeding) disorders that include haemophilia and von Willebrand disease, as well as immune deficiencies; reversal of warfarin; and prevention of haemolytic disease in newborns resulting from Rh factor incompatibilities. The company’s research and development programs are focused in areas, such as plasma replacement therapies, vaccines, ISCOMATRIX adjuvant, and therapeutic proteins. CSL Behring UK Limited was formerly known as ZLB Behring UK Ltd. and c...
Haywards Heath, RH16 1DB
Founded in 1982
Key Executives for CSL Behring UK Limited
Senior Vice President of Research and Development
Director of Public Relations
Vice President of Research and Development
Compensation as of Fiscal Year 2015.
CSL Behring UK Limited Key Developments
European Medicines Agency Approves Once Every Two Weeks Dosing Option For Hizentra(R) (Human Normal Immunoglobulin, SCIg)
Dec 5 13
CSL Behring UK Ltd. announced that the European Medicines Agency (EMA) has expanded the administration options for Hizentra(R), human normal immunoglobulin, SCIg, 20% liquid, to include dosing once every two weeks (fortnightly). Hizentra initially received EMA approval in 2011 as a 20%, once weekly SCIg replacement therapy for adults and children with PID to help treat existing or chronic infections and prevent new infections from occurring. Hizentra can also be stored at room temperature for up to 30 months meaning it is ready to use. Dosing once every two weeks with Hizentra can offer adult and paediatric patients consistent levels of IgG similar to weekly infusions, while providing patients with the option of infusing less frequently. The data to support dosing once every two weeks with Hizentra is based on the principles of pharmacometrics and pharmacokinetic modelling that included 3,800 data points for U.S. and EU clinical trials and 300 simulated trials. Hizentra is indicated for: Replacement therapy in adults and children in primary immunodeficiency (PID) syndromes such as: congenital agammaglobulinaemia and hypogammaglobulinaemia; common variable immunodeficiency; severe combined immunodeficiency; IgG subclass deficiencies with recurrent infections; Replacement therapy in myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries